I am thinking, there is no guarantee clomi will work if fluvoxamine isn't working, they are both known to 'work' for a longer time than other SSRIs, perhaps when one poops-out on enough SRI-based drugs, then no SRI will keep working. If that's the case, then you need to focus on the cause of the poop-out (for which the models, we all can admit, are highly theoretical at this point).
https://www.ncbi.nlm...pubmed/21508860
Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study.
BACKGROUND:
Several lines of evidence implicate glutamatergic neurotransmission in the pathophysiology of obsessive compulsive disorder (OCD). Sarcosine is an endogenous antagonist of glycine transporter-1. By blocking glycine uptake, sarcosine may increase the availability of synaptic glycine and enhance N-methyl-d-aspartate (NMDA) subtype glutamatergic neurotransmission. In this 10-week open-label trial, we examined the potential benefit of sarcosine treatment in OCD patients.
METHOD:
Twenty-six outpatients with OCD and baseline Yale-Brown Obsessive Compulsive Scale (YBOCS) scores higher than 16 were enrolled. Drug-naive subjects (group 1, n = 8) and those who had discontinued serotonin reuptake inhibitors for at least 8 weeks at study entry (group 2, n = 6) received sarcosine monotherapy. The other subjects (group 3, n = 12) received sarcosine as adjunctive treatment. A flexible dosage schedule of sarcosine 500 to 2000 mg/d was applied. The primary outcome measures were Y-BOCS and Hamilton Anxiety Inventory, rated at weeks 0, 2, 4, 6, 8, and 10. Results were analyzed by repeated-measures analysis of variance.
RESULTS:
Data of 25 subjects were eligible for analysis. The mean ± SD Y-BOCS scores decreased from 27.6 ± 5.8 to 22.7 ± 8.7, indicating a mean decrease of 19.8% ± 21.7% (P = 0.0035). Eight (32%) subjects were regarded as responders with greater than 35% reduction of Y-BOCS scores. Five of the responders achieved the good response early by week 4. Although not statistically significant, drug-naive (group 1) subjects had more profound and sustained improvement and more responders than the subjects who had received treatment before (groups 2 and 3). Sarcosine was tolerated well; only one subject withdrew owing to transient headache.
CONCLUSION:
Sarcosine treatment can achieve a fast therapeutic effect in some OCD patients, particularly those who are treatment naive. The study supports the glycine transporter-1 as a novel target for developing new OCD treatment. Large-series placebo-controlled, double-blind studies are recommended.
Sarcosine and Agmatine are dirt cheap, and are very low risk when taken at clinically relevant dosages. I don't see why you shouldn't experiment with them before moving to clomipramine. According to animal models, 200-400 mg of Agmatine per day is all you need for anti-ocd/anti-depressant potentiation effects, and 500-1000 mg Sarcosine.
I'm beginning to think the same regarding SSRI's and clomipramine. The only difference is that clomi's Ki-value for SERT is much lower (0.14–0.28) than fluvoxamine (2.2), but this doesn't say everything about efficacy I guess.
After all, I was on sertraline for 8 months and it had no effect at all.
So on one side there's a suspicion that long term use of SSRI's has something to do with the loss of response.
It isn't such a weird idea to focus on getting them work again, since I was able to tolerate them and it was a successful treatment.
On the other hand I do want to consider taking an anti-psychotic.
I seem to be dealing with an overactive thought process. Not the same as racing thoughts and/or intrusive voices, but maybe long term use of SSRI's does have influence on dopamine release?
I'll look into agmatine and sarcosine again and I'm dropping the idea of trying NAC for a second time.